Form 4: Arcutis Biotherapeutics CEO Todd Watanabe Sells Shares to Cover Tax Obligations

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 13,783 shares of common stock on May 2, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Summary

• Todd Franklin Watanabe, CEO of Arcutis Biotherapeutics, sold 13,783 shares of common stock on May 2, 2024.
• The sale was executed under a Rule 10b5-1 trading plan to cover tax obligations associated with the vesting of Restricted Stock Units.
• The shares were sold at a weighted average price of $8.7378, with individual trades ranging from $8.47 to $9.07.
• Following the transaction, Watanabe directly owns 860,750 shares of Arcutis Biotherapeutics common stock.
• Watanabe also has indirect ownership through various trusts and an LLC.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports a transaction. The sale of shares by an executive could be perceived negatively, but the explanation that it was for tax obligations under a 10b5-1 plan mitigates this.

Industry Context

This is a routine Form 4 filing related to insider transactions. It is common for executives to sell shares to cover tax obligations, especially after vesting of stock awards.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although the stated reason (tax obligations) should alleviate concerns.

Key Dates